Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Beginning in 2017, the QPP directly impacts your future Medicare physician fee schedule. With the repeal of the SGR, MACRA creates a 0.5% PFS increase for a couple of years and then freezes the fee schedule for several years. During the freeze, the published fee schedule represents the starting point, but what you are actually paid depends on whether you are subject to MIPS or participating in an Advanced APM. If you are subject to MIPS, your MIPS score during the performance year determines what percentage of the PFS you will receive during the payment year. Those subject to MIPS in 2018 will receive between 95 and 105% of the PFS in 2020. Where you lie on this continuum is dictated by your 2018 MIPS score. This +/- 5% corridor expands to +/- 7% in payment year 2021 and to +/- 9% in 2022 and beyond.
MIPS uses components of the three CMS incentive programs sunset by MACRA, adds a fourth new category, and rolls all four up to provide each practitioner with a MIPS score. That score on a scale of 0-100 is used to compare the performance of all physicians across the country. Physicians with a MIPS score equal to the national average in 2018 will receive the published PFS in 2020 without an adjustment. Those with a MIPS score exceeding the average will realize an upward adjustment in their 2020 fee schedule, while those with a MIPS score below the average will face a downward adjustment. It’s this differential payment to physicians, based on their MIPS score, which makes the QPP such a dramatic departure from prior Medicare physician reimbursement schemes. In essence, MIPS is a zero sum game, where the high performers are paid with funds collected by penalizing the poor performers.
Most of the MIPS categories are familiar to nephrologists:
Importantly, there are three groups of providers excluded from MIPS:
An alternative payment model (APM) is best described as a system for reimbursement that provides additional compensation as an incentive for the delivery of higher quality and more cost-efficient health care. There are dozens of APMs available today. The APMs of interest to the nephrologist fall into one of two categories; Advanced APMs, or so-called MIPS APMs. Advanced APMs are distinguished by the presence of three criterion:
Each year, CMS will publish the list of APMs that meet the criteria to be classified as an Advanced APM. That list includes the two-sided risk ESCO. Today Fresenius operates 24 of the 35 two-sided risk ESCOs. Last year all physicians participating in those ESCOs were determined to be Qualifying Participants. QPs were excluded from MIPS in 2017, and in 2019 they will receive a lump sum payment equivalent to 5% of their 2018 Part B book of business.
As a nephrologist, you may participate in a MIPS APM. The Medicare Shared Savings Program (MSSP) track 1 ACO is the most common MIPS APM. Fulfilling the MIPS requirements is substantially easier within a MIPS APM. Typically, the Advancing Care Information category within MIPS is the only category you are compelled to report for MIPS within a MIPS APM. The other three categories are either excluded or they are reported by the APM. While the MIPS APM does lessen the administrative overhead required to participate in MIPS, it’s important to recognize that all physicians within a MIPS APM receive the same MIPS score, and therefore all will see the same adjustment to their PFS during the payment year.
Last year, nephrologists began a new journey with respect to Medicare payment. The QPP represents a sea change which will see physician payment differentials based on performance within the program. CMS has created attractive financial incentives designed to increase participation in Advanced APMs like the ESCO. In conjunction with our nephrology partners, Fresenius recognized early success in the ESCO program, and we remain committed to actively participating in the national conversation as health care payment models evolve.
Dr. Terry Ketchersid is Senior Vice President and Chief Medical Officer for Fresenius Medical Care’s Integrated Care Group where he has clinical oversight over FMCNA’s value-based care initiatives and ESCO programs. He received his B.A. in chemistry from Austin College, his executive MBA from Duke University’s Fuqua School of Business and his MD degree from the University of Texas Southwestern Medical School.